BETTA PHARMACEUTICALS CO L

Betta L flat 0% on Oct 23, 2026: CNY 42.57, 17.7 bn cap, 19.36% month‑end drop, 200‑day SMA 54.56, 52‑week high 78.18, low 38.20

Betta Pharmaceuticals faces setbacks in eye‑care trials and oncology competition, yet its diversified pipeline and partnerships may cushion short‑term earnings and position it for future gains.

Betta L (300558.SZ) trades below its 200‑day average amid a 15% monthly drop—potentially a buy‑the‑dip if new clinical data or approvals lift the stock.